Berenberg Bank Reaffirms Hold Rating for GSK (NYSE:GSK)

GSK (NYSE:GSK - Get Free Report)'s stock had its "hold" rating reiterated by stock analysts at Berenberg Bank in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports.

Several other analysts have also recently weighed in on the stock. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a report on Monday, April 28th. BNP Paribas initiated coverage on shares of GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price on the stock. Wall Street Zen downgraded shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Finally, Morgan Stanley started coverage on shares of GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, GSK presently has an average rating of "Hold" and an average price target of $37.38.

GSK Trading Up 0.8%

Shares of NYSE GSK traded up $0.31 during trading hours on Tuesday, hitting $41.11. The company's stock had a trading volume of 3,203,636 shares, compared to its average volume of 4,830,241. GSK has a 12 month low of $31.72 and a 12 month high of $44.67. The stock has a market cap of $84.82 billion, a price-to-earnings ratio of 25.86, a P/E/G ratio of 1.12 and a beta of 0.51. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The business has a 50-day simple moving average of $37.48 and a 200-day simple moving average of $36.28.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The business had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. During the same quarter last year, the business posted $0.43 EPS. The business's revenue was up 2.1% on a year-over-year basis. On average, analysts anticipate that GSK will post 4.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GSK

Hedge funds and other institutional investors have recently bought and sold shares of the business. Strategic Financial Concepts LLC purchased a new stake in shares of GSK in the 4th quarter worth approximately $4,033,000. Stockman Wealth Management Inc. grew its stake in shares of GSK by 3.7% in the fourth quarter. Stockman Wealth Management Inc. now owns 217,200 shares of the pharmaceutical company's stock worth $7,346,000 after acquiring an additional 7,683 shares during the last quarter. MADDEN SECURITIES Corp purchased a new stake in shares of GSK in the fourth quarter worth $2,957,000. Columbia Asset Management bought a new position in shares of GSK during the fourth quarter valued at $233,000. Finally, Van ECK Associates Corp raised its position in shares of GSK by 14.6% in the 4th quarter. Van ECK Associates Corp now owns 844,039 shares of the pharmaceutical company's stock worth $28,545,000 after purchasing an additional 107,529 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.